Iovance Biotherapeutics is a biopharmaceutical company that develops and commercializes tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers, which work by expanding patient-derived T cells to recognize and destroy cancer cells unique to each individual. The company's lead product, Amtagvi (lifileucel), is an FDA-approved individualized T cell therapy for advanced melanoma administered through a network of authorized treatment centers, generating revenue from therapy delivery alongside sales of Proleukin (aldesleukin), an interleukin-2 product used in treatment regimens and manufacturing processes. Iovance operates the Iovance Cell Therapy Center, an FDA-approved centralized manufacturing facility with capacity for thousands of patients annually, and is advancing a pipeline of next-generation TIL therapies and genetically engineered platforms targeting melanoma, non-small cell lung cancer, and sarcomas across a global market of more than 100,000 eligible patients annually.